SMALL CELL LUNG CANCER

This study tests a new drug, ABBV-706, combined with atezolizumab against standard treatment for people with extensive-stage small cell lung cancer that hasn't been treated yet. About 180 adults will receive either the new combo at one of two doses or standard care. The goal is t…

This early-stage study tests the safety of combining the drug talazoparib with low-dose chest radiation in people with extensive-stage small cell lung cancer. About 24 participants who have finished initial chemotherapy without their cancer getting worse will take talazoparib pil…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study tests a new drug called ZG006 combined with standard immunotherapy (with or without chemotherapy) as a first treatment for people with extensive-stage small cell lung cancer. About 100 adults aged 18-75 will take part to see if the combination is safe and how well it w…

This study tests two different drug combinations for people with extensive stage small cell lung cancer, a type that has spread widely. About 90 participants will receive either teniposide plus cisplatin and serplulimab or etoposide plus cisplatin and serplulimab. The goal is to …

This study tests two experimental drugs, BL-B01D1 and SI-B003, alone or together in 100 people with extensive-stage small cell lung cancer that has not responded to prior treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. Participants mus…

This study tests a combination of two drugs, tarlatamab and ZL-1310, with or without a third drug (durvalumab) in people with small cell lung cancer that has come back after standard treatment. The main goal is to find safe doses and check for side effects. About 160 adults will …

This program offers early access to an investigational drug called ABBV-706 for people with small cell lung cancer who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet…

This study tests a new medicine called PF-08634404, given with chemotherapy, for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops after other treatments stop working. About 40 participants who have not yet been treated for T-SCLC…

This study tests whether combining two experimental drugs (ZG006 and ZG005) can shrink tumors in people with advanced small cell lung cancer or neuroendocrine carcinoma. About 350 adults aged 18-70 will receive the combination to check safety and effectiveness. The goal is to see…

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan, alone or together, in people with advanced small cell lung cancer that stopped responding to prior treatment. About 262 participants will receive these treatments to see if they shrink tumors and are safe…

This early-phase study tests a new drug called NN3201, designed to find and attack cancer cells that have a specific protein called c-Kit. The trial includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others.…

This early-stage study tests a new drug called DXC014 in people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goal is to check safety and find the right dose. About 150 participants will take part in this first-in-human tria…

This study is for people newly diagnosed with extensive-stage small cell lung cancer that has spread. Researchers want to see if adding focused radiation to the standard treatment of durvalumab and chemotherapy can help people live longer without their cancer getting worse. About…

This study tests a new drug, ZL-1310, designed to target and kill cancer cells in people with small cell lung cancer that has returned after initial treatment. About 480 adults will receive either ZL-1310 or a standard treatment chosen by their doctor. The goal is to see if ZL-13…

This study tests a new drug (YL201) combined with ivonescimab in 260 adults with advanced solid tumors, including lung cancers. The goal is to see if the combination is safe and can shrink tumors. Participants must have good organ function and not be eligible for local curative t…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This early-phase study tests a new drug, BG-68501, in people with advanced solid tumors (like breast, ovarian, lung, or stomach cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors when used alone or with other…

This study tests a combination of the drug serplulimab plus chemotherapy in people whose lung cancer has changed from one type (EGFR-mutated non-small cell) to another (small cell) after prior treatment. About 66 adults aged 18-75 in China will receive the treatment to see if it …

This early-phase study tests a new targeted drug (NMS-03305293) combined with chemotherapy (Temozolomide) in about 10 people whose small cell lung cancer has returned after prior treatments. The main goal is to check safety and side effects, while also seeing if the combination c…

This study tests a new combination of drugs (chidamide, a PD-L1 inhibitor, and chemotherapy) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if it helps control the cancer longer. About 36 adults will receive the treatment for 4 c…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This study tests whether adding the drug tarlatamab to standard chemotherapy helps people with advanced small-cell lung cancer live longer. About 330 adults who have not yet been treated will be randomly assigned to receive either the new combination or standard treatment alone. …

This early-phase trial is testing a new drug called ST-001 in people with small cell lung cancer that has returned or stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects. About 44 participants will receive the drug throug…

This study tests whether adding a new drug called cirtuvivint to standard chemotherapy can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will receive the combination…

This study looks at how well the drug T-DXd works for people with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. About 100 adults in the US will be followed to see if their tumors shrink or stop growing. The goal is to u…

This study tests a new drug combination (SKB500) in 80 adults with small cell lung cancer. The goal is to see if it is safe and can shrink tumors or slow the disease. Participants must be 18-75 and have extensive-stage cancer that has not been treated much before.

This study tests an experimental drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The first part finds a safe dose, and the second part checks how well it shrinks tumors. About 265 adults aged 18 to 75 with good performance status are …

This study tests the drug alisertib in people with advanced small cell lung cancer whose disease has worsened after standard treatments like chemotherapy and immunotherapy. About 80 adults will take alisertib alone to see if it shrinks tumors or slows the cancer. The goal is to f…

This study tests a new drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or can't tolerate them. The goal is to find a safe dose and see if the drug can shrink tumors. About 54 adults aged 18 to 75 will tak…

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This early-phase study tests a new drug, KIVU-107, in about 76 adults with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goal is to find the…

This study tests a new drug called IDE849 in people with cancers that have a specific marker called DLL3, including small cell lung cancer and other solid tumors. The trial has two parts: first to check safety and find the right dose, then to see if the drug shrinks tumors or slo…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink or control the tumors. About 350 participants will take part in this early-phase trial.

This study tests an experimental pill called veonetinib (AL8326) in people with advanced small cell lung cancer, non-small cell lung cancer, or kidney cancer that has come back or spread. The goal is to find the best dose and see if it shrinks tumors. About 80 adults will take pa…

This study tests a new drug called ZG006 against standard chemotherapy in 420 adults with small cell lung cancer that has come back. The main goal is to see if ZG006 helps people live longer. Participants will be randomly assigned to receive either ZG006 or a chemotherapy chosen …

This study tests a combination of two drugs, monalizumab and durvalumab, along with standard chemotherapy, for people with small cell lung cancer. The goal is to see if this mix helps keep the cancer from growing longer. About 84 adults with either extensive-stage or limited-stag…

This study tests whether a new drug called AK112 can help prevent lung cancer from coming back in people with limited-stage small cell lung cancer who have finished chemotherapy and radiation. About 560 participants will receive either AK112 or a placebo. The goal is to see if th…

This early-phase study tests a new drug called BL-M14D1 in people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have spread and no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, a…

This early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the …

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 470 adults will take part.

This study tests a drug called onvansertib in about 37 people with small cell lung cancer that did not respond to or could not tolerate chemotherapy. Onvansertib blocks a protein that cancer cells need to repair themselves, aiming to shrink tumors. The main goal is to see how man…

This early-phase trial is testing whether adding acetazolamide (a drug that blocks carbonic anhydrase) to standard chemotherapy and radiation or immunotherapy can help treat small cell lung cancer. About 27 adults with either localized or extensive small cell lung cancer will tak…

This study is testing whether a precise type of radiation called stereotactic radiosurgery (SRS) can help people with small cell lung cancer that has spread to the brain. About 62 adults with up to 20 brain tumors will receive SRS, and researchers will track how many are alive af…

This study tests the drug fingolimod (currently used for multiple sclerosis) in people with advanced non-small cell or small cell lung cancer whose cancer has worsened after standard treatments. The goal is to see if the drug is safe and can shrink tumors or slow cancer growth. A…

This early-stage study tests a new drug called BL-M14D1 in people with advanced small cell lung cancer or other neuroendocrine cancers that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 adults will take part, a…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study tests a new drug, ifinatamab deruxtecan, against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive the new drug or a doctor-chosen therapy. The goal is to see if the new…

This study tests whether adding trilaciclib to the standard drug lurbinectedin can lower the risk of dangerous low white blood cell counts (neutropenia) in people with advanced small cell lung cancer that has stopped responding to initial treatment. About 30 adults will receive t…

This study tests a special PET scan that uses a radioactive tracer to find a protein called DLL3 on small cell lung cancer cells. The goal is to see if this imaging method is safe and can show where the cancer is in the body. About 53 people with small cell lung cancer or similar…

This study is for people with small-cell lung cancer who choose not to have preventive brain radiation. It compares a powerful 7T MRI to the usual 1.5T/3T MRI to see if it can detect very small brain metastases earlier. About 20 participants will get both scans over time. The goa…

This study is testing a new type of PET/CT scan that uses a special tracer called 18F-T2 to find cancers that have high levels of a protein called CAIX. About 200 adults with cancers like kidney, bladder, lung, or breast cancer will get this scan to see if it works better than th…

This study tests a new radioactive probe called PFD3 that targets a protein (DLL3) found on small cell lung cancer cells. Using PET/CT scans, doctors hope to see tumors more clearly and assess the cancer's spread. About 30 adults with confirmed small cell lung cancer will receive…

This study tests whether a special immune-boosting nutrition plan can lower the chance of severe throat inflammation (esophagitis) in lung cancer patients receiving chest radiation. About 121 adults with lung cancer will be randomly assigned to get either the immunonutrition or s…

This study explores whether a Hospital-at-Home program can safely and effectively monitor people with small cell lung cancer after they receive the drug tarlatamab, instead of keeping them in the hospital. About 70 adults will be enrolled. The goal is to see if this approach redu…

This study is for people with extensive stage small cell lung cancer. It aims to learn more about the disease by analyzing tumor tissue and blood samples over time. Researchers will look at genetic changes and other markers to see how they relate to treatment outcomes. The study …

This study gathers tumor samples, blood, and health information from 2,000 adults with certain lung and thymic cancers. Researchers will use these samples to study the disease's biology and find better ways to diagnose and treat it. Participants give samples and have scans, then …